Immunotherapy for Prostate Cancer: Sipuleucel-T & Checkpoint Inhibitors
- What is immunotherapy for prostate cancer?
- Sipuleucel-T (Provenge) – cancer vaccine
- Who qualifies for sipuleucel-T?
- Effectiveness of sipuleucel-T – survival benefit
- Checkpoint inhibitors (pembrolizumab) – for MSI-H tumors
- Other immunotherapies – clinical trials only
- Side effects – infusion reactions, autoimmune effects
- Immunotherapy vs. other treatments – comparison
- Interactive FAQ – 9 questions about immunotherapy for prostate cancer
What is immunotherapy for prostate cancer?
Immunotherapy is a type of cancer treatment that harnesses the body's immune system to fight cancer. Unlike chemotherapy (which directly kills cancer cells) or hormone therapy (which starves cancer cells), immunotherapy activates immune cells (T-cells) to recognise and destroy cancer cells.
Immunotherapy has revolutionised treatment for many cancers (melanoma, lung, kidney), but its role in prostate cancer is limited. Currently, only two immunotherapies are approved for prostate cancer: sipuleucel-T (Provenge) and pembrolizumab (Keytruda) for rare subtypes.
Sipuleucel-T (Provenge) – cancer vaccine
Sipuleucel-T (Provenge) is a therapeutic cancer vaccine approved for metastatic castration-resistant prostate cancer (mCRPC). It is not a preventive vaccine (like HPV vaccine) – it treats existing cancer.
How it works:
- Patient undergoes leukapheresis (blood is drawn, immune cells are collected)
- Immune cells (antigen-presenting cells) are sent to a lab
- Cells are exposed to PAP-GM-CSF (a protein that targets prostate cancer)
- Activated cells are infused back into the patient (3 doses, 2 weeks apart)
- The activated immune cells then attack prostate cancer cells
Treatment schedule:
- 3 total infusions, 2 weeks apart
- Each cycle: leukapheresis (3 hours) + infusion (1 hour)
- Total treatment time: 6 weeks
Who qualifies for sipuleucel-T?
Sipuleucel-T is approved for a narrow group of patients:
- Metastatic castration-resistant prostate cancer (mCRPC)
- Asymptomatic or minimally symptomatic (no or mild cancer-related pain)
- Good performance status (able to undergo leukapheresis)
- Life expectancy >6 months
Who is NOT a candidate:
- Symptomatic mCRPC (pain requiring opioids)
- Visceral metastases (liver, lung) – less effective
- Rapidly progressive disease
- Prior chemotherapy (can still use, but less benefit)
Effectiveness of sipuleucel-T – survival benefit
The landmark IMPACT trial (2010) led to FDA approval:
- Median overall survival improvement: 4.1 months (25.8 vs. 21.7 months)
- PSA response: Does NOT lower PSA (PSA is not a marker of response)
- Tumor shrinkage: Rare (does not shrink tumors)
- Quality of life: Preserves or improves quality of life
Real-world effectiveness:
- Survival benefit of 4-6 months in clinical practice
- Best in patients with slower disease progression
Checkpoint inhibitors (pembrolizumab) – for MSI-H tumors
Checkpoint inhibitors (pembrolizumab/Keytruda, nivolumab/Opdivo) block PD-1/PD-L1, releasing the "brakes" on the immune system. They are highly effective in some cancers but only work in a small subset of prostate cancer patients.
FDA approval:
- Pembrolizumab (Keytruda) approved for any solid tumor with MSI-H (microsatellite instability-high) or dMMR (mismatch repair deficiency)
- Only 2-5% of prostate cancers have MSI-H/dMMR
- These tumors are often aggressive and occur in younger men
Effectiveness in MSI-H prostate cancer:
- Response rate: 40-50% (much higher than in MSI-stable prostate cancer)
- Durable responses (years)
Testing for MSI-H/dMMR:
- Recommended for all men with metastatic prostate cancer (NCCN guidelines)
- Testing on biopsy tissue (immunohistochemistry for MMR proteins or PCR for MSI)
Other immunotherapies – clinical trials only
Several other immunotherapies are being studied but are not FDA-approved for prostate cancer:
- Ipilimumab (Yervoy): CTLA-4 inhibitor – tested in trials, not approved due to toxicity and modest benefit
- Bispecific T-cell engagers (BiTEs): Target PSMA (stepping on cancer cells)
- CAR-T cells: Genetically engineered T-cells targeting PSMA – early trials
- PSMA-targeted radioligand therapy (Lu-177-PSMA): Not immunotherapy (radiation), but often discussed alongside
Side effects – infusion reactions, autoimmune effects
Immunotherapy side effects differ from chemotherapy:
Sipuleucel-T side effects (common, mild):
- Infusion reactions (chills, fever, fatigue) – 70-80%
- Headache, myalgia, nausea
- Rarely, more severe infusion reactions (hypotension, dyspnoea)
Checkpoint inhibitor side effects (pembrolizumab):
- Immune-related adverse events (irAEs): Autoimmune reactions
- Common: fatigue, rash, diarrhoea, hypothyroidism (manageable)
- Serious (5-10%): Pneumonitis (lung inflammation), colitis, hepatitis, nephritis
- Require steroids (prednisone) or withholding immunotherapy
Immunotherapy vs. other treatments – comparison
| Feature | Sipuleucel-T | Checkpoint Inhibitors | Chemotherapy (Docetaxel) | Hormone Therapy (ADT) |
|---|---|---|---|---|
| Mechanism | Activates immune cells | Blocks PD-1/PD-L1 | Kills dividing cells处理方法Lowers testosterone | |
| Approval for prostate cancer | Yes (mCRPC, asymptomatic) | Only for MSI-H/dMMR | Yes (mHSPC, mCRPC) | Yes (all stages) |
| PSA response | No | Occasional (MSI-H) | Yes (50% decline) | Yes |
| Tumor shrinkage | No | Yes (MSI-H) | Yes | Yes|
| Survival benefit | 4-5 months处理方法Durable in responders | 2-17 months处理方法Years|||
| Side effects | Infusion reactions处理方法的Autoimmune (pneumonitis, colitis) | Neutropenia, neuropathy处理方法Hot flashes, fatigue
Interactive FAQ – Immunotherapy for prostate cancer
For most men, no – prostate cancer is "cold" and doesn't respond well to immunotherapy. Sipuleucel-T provides a modest survival benefit. Checkpoint inhibitors only work in 2-5% of men (MSI-H tumors).
A therapeutic cancer vaccine that activates a patient's own immune cells to attack prostate cancer. Used for asymptomatic or minimally symptomatic mCRPC.
No – sipuleucel-T does not lower PSA. PSA is not a marker of response. Response is measured by survival and quality of life.
Microsatellite instability-high – a rare subtype (2-5% of prostate cancers) that responds well to checkpoint inhibitors (pembrolizumab).
Men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) and good performance status.
Sipuleucel-T: infusion reactions (chills, fever). Checkpoint inhibitors: autoimmune side effects (pneumonitis, colitis, rash).
For most men, no – chemotherapy is more effective. Immunotherapy has a limited role (sipuleucel-T for asymptomatic mCRPC, checkpoint inhibitors for rare MSI-H tumors).
3 infusions over 6 weeks. Each dose requires leukapheresis (blood draw to collect immune cells) followed by infusion.
Yes – Medicare and most private insurers cover sipuleucel-T for eligible patients. Cost is approximately $100,000 for the full course.
Disclaimer: This information is for educational purposes. Immunotherapy decisions should be made with a medical oncologist. Consult a specialist at Vivekananda Hospital.